SLC5A2 and type 2 diabetes mellitus: Several large-scale clinical trials from 2015 (EMPA-REG OUTCOME, DECLARE–TIMI 58, CANVAS Program, and CREDENCE trials) evaluated the cardiorenal protective effects of SGLT2 inhibitors in patients with type 2 diabetes (6–9).